Effectiveness

Aerogen facilitates effective medication delivery across multiple respiratory modalities^3-8†

• In studies, ~4x more drug deposition was achieved with Aerogen during IMV,^†3,4 NIV^‡5, and HF,⁶ and ~6x more drug deposition during SV^‡7 versus jet nebulisers

^†When placed 15 cm from the Y-Piece in a heated setting; in-vitro model
^‡Study performed in healthy subjects 

Patient care

Aerogen improves patient care in response to aerosolised medication^9-11

In studies assessing bronchodilator delivery across several respiratory modalities, Aerogen Solo, when compared with jet nebulisers, was associated with:

• Improvements in lung function in patients undergoing NIV^†9
• Comparable bronchodilator efficacy^‡ during HF¹⁰
• Reductions in hospital admission rates, emergency department median length of stay, and in the number of treatments and time required to achieve symptom control^§  in SV patients^¶11 

^†Between-group difference in FEV1, FVC, breathlessness score, RR, and PaCO2 from  baseline to 120 minutes in patients with acute exacerbation of COPD
^‡As defined by relative increase in FEV1 in patients with reversible obstructive lung disease
^§Defined as achieving a mild asthma score following an asthma exacerbation
^¶When used in conjunction with Aerogen Ultra 

Workflow

Aerogen simplifies the workflow

• Aerogen Solo is a closed-circuit aerosol drug delivery system,² which eliminates the need to open the circuit when administering medication during IMV or NIV  
• Aerogen Solo delivers integrated aerosol delivery with HF and can be used in conjunction with Aerogen Ultra for aerosol drug delivery in SV patients²
• Aerogen Solo is intended for the aerosolisation of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser²
• One system can be used throughout a patient's respiratory journey (IMV, NIV, HF, SV),² supporting continuity of care